LPCN
LPCN
NASDAQ · Pharmaceuticals

Lipocine Inc

$2.33
-0.01 (-0.43%)
Financial Highlights (FY 2026)
Revenue
2.99M
Net Income
-14,566,769
Gross Margin
Profit Margin
-487.1%
Rev Growth
+58.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 28.1% 28.1%
Operating Margin -524.7% -472.2% 13.6% 14.9%
Profit Margin -487.1% -462.7% 16.1% 15.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.99M 1.89M 22.16M 17.20M
Gross Profit 6.23M 4.83M
Operating Income -15,693,551 -8,932,580 3.02M 2.56M
Net Income -14,566,769 -8,291,229 3.56M 2.74M
Gross Margin 28.1% 28.1%
Operating Margin -524.7% -472.2% 13.6% 14.9%
Profit Margin -487.1% -462.7% 16.1% 15.9%
Rev Growth +58.1% +58.1% +9.7% +22.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 4.92M 5.58M
Total Equity 36.70M 40.60M
D/E Ratio 0.13 0.14
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -15,599,774 -9,372,492 4.85M 3.77M
Free Cash Flow 3.49M 2.02M